TSHA
Taysha Gene Therapies, Inc. · NASDAQ
- Sector Health Technology
- Industry Biotechnology
- Website ayshagtx.com
- Employees(FY) 65
- ISIN US8776191061
Performance
-15.9%
1W
-2.43%
1M
-10.27%
3M
-34.95%
6M
+13.56%
YTD
+11.67%
1Y
Profile
Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 Deficiency; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center to develop and commercialize transformative gene therapy treatments. The company was incorporated in 2019 and is based in Dallas, Texas.
Technical Analysis of TSHA 2024-11-20
Technical Scores and Rating
Moving Average Score
Oscillator Score
Technical Rating
Recent News & Updates
- 2024-11-13 23:51
Q3 2024 Taysha Gene Therapies Inc Earnings Call(Yahoo Finance)
- 2024-11-13 13:16
- 2024-11-13 04:15
- 2024-11-13 03:01
- 2024-11-05 19:00
- 2024-11-01 04:30
- 2024-10-21 20:00
- 2024-10-16 03:42
- 2024-10-14 00:00
- 2024-10-03 20:01
- 2024-10-02 16:55
- 2024-09-25 20:00
- 2024-09-06 08:00
- 2024-09-05 20:00
- 2024-08-18 09:45
- 2024-08-12 08:01
- 2024-08-11 21:10
- 2024-08-11 20:01
- 2024-08-11 10:02
- 2024-08-05 08:00
- 2024-08-04 20:00
- 2024-08-02 08:00
- 2024-08-01 20:00
- 2024-07-05 08:00
- 2024-07-04 20:00
- 2024-07-02 06:40
Daily – Vickers Top Buyers & Sellers for 07/02/2024(Argus Research)
- 2024-07-01 09:59
Insider Buyers At Taysha Gene Therapies Sitting On US$24m Profit(Simply Wall St.)
- 2024-07-01 08:59
- 2024-06-27 08:01
- 2024-06-26 09:59
Page 1 of 7
previousnext
Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.